Pfizer Inc. (PFE)
NYSE · Healthcare · Drug Manufacturers - General
$27.41−1.40%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $156B
- P/E (trailing)
- 36.5
- Forward P/E
- 9.5
- Dividend yield
- 6.3%
- 52-week range
- $23.62 – $29.21
- 52-week change
- +5.82%
- EPS (trailing)
- $0.75
- Analyst rating
- 2.5 Buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $62.6B (−1.65%)
- Net income
- $7.8B
- Diluted EPS
- $1.36
- Free cash flow
- $9.1B
From the company’s annual report on SEC EDGAR.
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands.
Headquarters: New York, United States · 75,000 employees · pfizer.com